BCR and diffuse large B-cell lymphoma: Therapy resistance due to mitochondria is also evident in DLBCL, wherein the OXPHOS-DLBCL subtype, which relies on mitochondrial bioenergetics, shows insensitivity to BCR signaling inhibition.